QUECTEL-WIRELESS
21.6.2022 14:02:48 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced its dual-band multi-constellation GNSS module LC29H . Built using the Airoha AG3335 platform, the LC29H is available in multiple variants and optionally integrates RTK and DR. The LC29H series offers high performance, power-efficient solutions to meet market needs of high-precision positioning at the centimeter and decimeter levels. These modules are perfectly suited to an expanding market for autonomous lawn mowers, drones, precision agriculture, micro-mobility scooters and delivery robots as well as other industrial and autonomous applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005631/en/
“High precision positioning with centimeter level accuracy is becoming increasingly vital for many new IoT applications. Robotics, UAV and industrial applications needing precise navigation are driving new market requirements and we are very excited to launch our newest generation of high-precision positioning modules,” said Patrick Qian, CEO of Quectel. “With our focus of providing best-in-class, easy-to-use and affordable solutions to our customers, we believe the IoT market is ready for mass adoption of cm-level positioning modules for a wide range of scenarios.”
The LC29H concurrently receives and processes signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS maximizes satellite signal availability. The module supports L1 and L5 dual-band signal reception, thereby ensuring that terminals can speed up convergence time, improve positioning accuracy, and achieve fast response times even when the signal is interrupted. The dual band design significantly mitigates the multipath effect experienced near high-rise buildings or in deep urban canyons, and provides reliable positioning performance.
In addition, some versions contain 6-axis IMU inertial sensors (3-axis accelerometer + 3-axis gyroscope), and integrate RTK and DR positioning algorithms, allowing for continuous lane-level accurate positioning in scenarios where the satellite signal is partially or completely blocked, such as underground parking lots, tunnels, urban-canyons or forests. When the satellite signal is re-acquired, the LC29H combines inertial sensor data with GNSS signals, and the integrated navigation can provide fast convergence times and decimeter level positioning accuracies.
In order to improve the performance when used with a passive Antenna, the LC29H has a built-in LNA and an internal SAW filter, ensuring high sensitivity and excellent positioning accuracy.
The LC29H adopts a 12nm process, dual-frequency receiver chip and advanced low-power management, thereby enabling low-power GNSS sensing and position fixing. This makes the module an ideal solution for power-sensitive and battery-powered devices including handheld devices, asset trackers, and shared vehicles.
Featuring an LCC form factor and an industry standard footprint size of 12.2 mm × 16.0 mm × 2.5 mm, the LC29H series design allows for easy system integration and smooth migration of legacy designs to the latest high precision GNSS technologies.
The LC29H is available in four product variants each targeting different application scenarios. The LC29H(EA) offers a perfect solution for a growing market of agricultural drones as well as electricity power detection terminals, and is able to improve the anti-interference capability of complex systems. The LC29H(BA) is well suited to agricultural machinery and specialized vehicles, and the LC29H(DA) can enable centimeter-level accuracy in connected lawnmowers and safety helmets at competitive cost.
Additionally, the LC29H can be bundled with Quectel’s wide range of off-the-shelf and customized GNSS antennas . Both passive and active antennas are provided to satisfy customer requirements for high precision positioning. Customized connector types and cable lengths are available as along with comprehensive antenna design support including simulation and testing services. The manufacturing of customized antenna solutions is also available to fast track customer product development.
The LC29H will be showcased at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com
, LinkedIn
, Facebook
, and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005631/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom